Phase 3 Crohn's Disease and Colitis Trial, Recruiting NCT07577843 Sponsor: Janssen Research & Development, LLC Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 3 Crohn's Disease and Colitis Trial, Recruiting

NCT07577843
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Crohn's disease (CD) or Crohn's disease with fistulas (tunnels forming between body parts), and this diagnosis was confirmed at least 12 weeks before the study screening, with both a camera examination of the gut and a tissue sample supporting that diagnosis.
  • Your Crohn's disease is considered moderate to severe, based on a scoring system called CDAI (a score between 220 and 450), and you also have either frequent loose/very soft stools (an average of 4 or more per day) or notable abdominal pain (an average pain score of 2 or more per day).
  • A camera examination of your small intestine and colon (ileocolonoscopy), reviewed centrally, confirms that you have moderately to severely active Crohn's disease in your small intestine and/or colon.
  • You have previously tried approved treatments for Crohn's disease that either did not work well enough, stopped working over time, or caused side effects you could not tolerate.

Who may not be able to join:

  • You have been diagnosed with a different type of bowel condition, such as indeterminate colitis, microscopic colitis, ischemic colitis, or ulcerative colitis, or your symptoms strongly suggest ulcerative colitis.
  • You have complications from Crohn's disease, such as significant narrowing of the bowel, or any other issue that might require bowel surgery during the study.
  • You currently have a working stoma or ostomy (an opening in your abdomen used to divert waste into a bag).
  • You have short bowel syndrome, are missing more than 2 of the 5 sections of your lower intestine, or have another medical condition that would make it difficult to accurately measure your response to the study treatment using standard tools like the CDAI score (confirm with trial site).
  • You currently have, or are suspected of having, an abscess (a pocket of infection/pus) in your body.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Australian sites

IBD SA, Kurralta Park,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
22 May 2026
Est. completion
12 June 2028

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇮🇱 Israel 🇯🇵 Japan Turkey (Türkiye) 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Co-Primary: Percentage of Participants with Clinical Remission at Week 48; Co-Primary: Percentage of Participants with Endoscopic Remission at Week 48

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov